Document is current
Any future updates will be listed below
-
Authors
Kocaata, Zeki
Wilke, Thomas
Fischer, Franz
Welte, Robert
Einsele, Hermann
-
Funding
Funding for this research was provided by:
GlaxoSmithKline GmbH & Co. KG.
- License Information
-
More Information
Article History
Accepted: 16 May 2022
First Online: 24 June 2022
Declarations
:
: This study was supported by GlaxoSmithKline GmbH & Co. KG.
: Franz Fischer and Robert Welte are employees of GlaxoSmithKline GmbH & Co. KG. Zeki Kocaata participated in this work as an employee of Ingress-Health and has no conflict of interest to declare. Thomas Wilke is the founder of IPAM e.V. and received honoraria from Boehringer Ingelheim Pharma, Bayer Health Care, GSK, Novartis, Sanofi-Aventis, Bristol Myers Squibb, Pfizer, and other pharmaceutical companies. Hermann Einsele, who is working as a physician in the field of oncology, supported the study as a scientific advisor.
: As the study addressed a retrospective anonymized dataset, no ethical review was needed. However, the study protocol was reviewed by a scientific steering committee and the data owner (statutory health insurance, AOK PLUS). The work on the dataset conformed to all social security data protection requirements.
: As the study addressed a retrospective anonymized dataset, no informed consent of patients was needed.
: The study was reviewed by a scientific steering committee and the data owner and approved for publication. All co-authors consented to publish the manuscript.
: The dataset used to conduct the analysis is not publicly available. All data needed to evaluate the conclusions in the paper are present in the main text and/or the Supplementary Materials.
: All data needed to evaluate the conclusions in the paper are present in the main text and/or the Supplementary Materials. Statistical analyses were done using standard applications of the software packages mentioned in the method sections. Custom algorithms applied (i.e., identification of therapy lines) have been described in the main text and/or the Supplementary Materials.
: Conceptualization: Z.K., T.W., F.F., R.W.; Methodology: Z.K., T.W., F.F., E.H.; Formal analysis: Z.K.; Writing–original draft preparation: T.W., Z.K.; Writing–review and editing: Z.K., T.W., F.F., R.W.,E.H; Supervision: F.F., R.W.
